Advertisement
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical companyderiving significant new patient benefits from proven CNS drugs. Transceptdevelopment projects leverage new understanding of CNS conditions to provideadditional uses and enhanced clinical benefits for existing active agents. Thelead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge),is a low dose sublingual formulation of zolpidem for the treatment of insomniain patients who awaken in the middle of the night and have difficultyreturning to sleep. Phase 3 clinical trials have been completed forIntermezzo(R) and Transcept plans to submit an NDA in the third quarter of2008. Another product being developed by Transcept is TO-2060, a novel,fixed-dose combination of olanzapine and ondansetron for the treatment ofdopamine associated psychiatric disorders. For further information, pleasevisit the company's website at: http://www.transcept.com.Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Michael Gill Investors / Media Director of Communications Stephanie Carrington / Jason Rando (510) 215-3575 (646) 536-7017 / 7025 [email protected] [email protected] [email protected]
SOURCE Transcept Pharmaceuticals, Inc.
